Key result
Patients with Facioscapulohumeral muscular dystrophy had significantly altered serum biomarkers compared to healthy controls, including a 6.52-fold increase in creatine kinase MB fraction (P<0.0001).
Why the study?
What serum biomarkers are elevated in Facioscapulohumeral muscular dystrophy compared to healthy controls?
Population
22 Facioscapulohumeral muscular dystrophy patients and 23 age and gender-matched healthy controls
Comparison
Commercial multiplex, microsphere-based… vs Healthy controls
Design
Cross-sectional
Authors
Loading...
Elevated CKMB and other biomarkers in FSHD are hypothesis-generating; prospective studies needed before any clinical application.
Cross-Sectional (n=45)
What serum biomarkers are elevated in Facioscapulohumeral muscular dystrophy compared to healthy controls?
Effect estimate: 6.52 fold change
p-value: p=<0.0001
Multiplex screening identified 7 potential serum biomarkers, including CKMB and PLAT, that are elevated in Facioscapulohumeral muscular dystrophy.
Statland et al. (2014) conducted a cross-sectional in Facioscapulohumeral muscular dystrophy (n=45). Facioscapulohumeral muscular dystrophy vs. Healthy controls was evaluated on Serum biomarkers below a 5% false discovery rate (e.g., creatine kinase MB fraction) (6.52 fold change, p=<0.0001). Patients with Facioscapulohumeral muscular dystrophy had significantly altered serum biomarkers compared to healthy controls, including a 6.52-fold increase in creatine kinase MB fraction (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: